Found: 62
Select item for more details and to access through your institution.
Androgens alter the heterogeneity of small extracellular vesicles and the small RNA cargo in prostate cancer.
- Published in:
- Journal of Extracellular Vesicles, 2021, v. 10, n. 10, p. 1, doi. 10.1002/jev2.12136
- By:
- Publication type:
- Article
Safety of pazopanib and sunitinib in treatment-naive patients with metastatic renal cell carcinoma: Asian versus non-Asian subgroup analysis of the COMPARZ trial.
- Published in:
- Journal of Hematology & Oncology, 2018, v. 11, n. 1, p. N.PAG, doi. 10.1186/s13045-018-0617-1
- By:
- Publication type:
- Article
Clinical Effectiveness of Second-line Sunitinib Following Immuno-oncology Therapy in Patients with Metastatic Renal Cell Carcinoma: A Real-world Study.
- Published in:
- Clinical Genitourinary Cancer, 2021, v. 19, n. 4, p. 354, doi. 10.1016/j.clgc.2021.03.006
- By:
- Publication type:
- Article
Low rate of severe-end-stage kidney disease after SABR for localised primary kidney cancer.
- Published in:
- Radiation Oncology, 2024, v. 19, n. 1, p. 1, doi. 10.1186/s13014-024-02413-w
- By:
- Publication type:
- Article
Motesanib diphosphate (AMG 706), an oral angiogenesis inhibitor, demonstrates clinical efficacy in advanced thymoma.
- Published in:
- Acta Oncologica, 2009, v. 48, n. 4, p. 619, doi. 10.1080/02841860802495362
- By:
- Publication type:
- Article
Small cell carcinoma of unknown primary presenting with disease confined to the central nervous system.
- Published in:
- Acta Oncologica, 2009, v. 48, n. 2, p. 317, doi. 10.1080/02841860802311817
- By:
- Publication type:
- Article
Determinants of outcome following PSMA-based radioligand therapy and mechanisms of resistance in patients with metastatic castration-resistant prostate cancer.
- Published in:
- Therapeutic Advances in Medical Oncology, 2023, p. N.PAG, doi. 10.1177/17588359231179309
- By:
- Publication type:
- Article
Safety of Lutetium-177 prostate-specific membrane antigen-617 (PSMA-617) radioligand therapy in the setting of severe renal impairment: a case report and literature review.
- Published in:
- Therapeutic Advances in Medical Oncology, 2023, p. 1, doi. 10.1177/17588359231177018
- By:
- Publication type:
- Article
Beyond cabazitaxel: Late line treatments in metastatic castration resistant prostate cancer: A retrospective multicentre analysis.
- Published in:
- Asia Pacific Journal of Clinical Oncology, 2022, v. 18, n. 6, p. 642, doi. 10.1111/ajco.13732
- By:
- Publication type:
- Article
<sup>68</sup>Ga‐prostate‐specific membrane antigen (PSMA) PET/CT as a clinical decision‐making tool in biochemically recurrent prostate cancer.
- Published in:
- Asia Pacific Journal of Clinical Oncology, 2022, v. 18, n. 5, p. e204, doi. 10.1111/ajco.13595
- By:
- Publication type:
- Article
Treatment outcomes for patients with metastatic castrate‐resistant prostate cancer following docetaxel for hormone‐sensitive disease.
- Published in:
- Asia Pacific Journal of Clinical Oncology, 2021, v. 17, n. 1, p. 36, doi. 10.1111/ajco.13447
- By:
- Publication type:
- Article
Treatment selection for first‐line metastatic renal cell carcinoma in Australia: Impact of new therapy options.
- Published in:
- Asia Pacific Journal of Clinical Oncology, 2019, v. 15, p. 3, doi. 10.1111/ajco.13289
- By:
- Publication type:
- Article
Targeted agents for the systemic treatment of advanced hepatocellular carcinoma.
- Published in:
- Asia Pacific Journal of Clinical Oncology, 2009, v. 5, n. 2, p. 76, doi. 10.1111/j.1743-7563.2009.01202.x
- By:
- Publication type:
- Article
Predicting the response to targeted therapy in metastatic colorectal cancer.
- Published in:
- Asia Pacific Journal of Clinical Oncology, 2008, v. 4, n. 4, p. 208, doi. 10.1111/j.1743-7563.2008.00215.x
- By:
- Publication type:
- Article
Combination of PARP Inhibitors and Androgen Receptor Pathway Inhibitors in Metastatic Castration-Resistant Prostate Cancer.
- Published in:
- Drugs, 2024, v. 84, n. 9, p. 1093, doi. 10.1007/s40265-024-02071-y
- By:
- Publication type:
- Article
Continuous Flow Deformability-Based Separation of Circulating Tumor Cells Using Microfluidic Ratchets.
- Published in:
- Small, 2016, v. 12, n. 14, p. 1909, doi. 10.1002/smll.201503639
- By:
- Publication type:
- Article
Guiding management of therapy in prostate cancer: time to switch from conventional imaging to PSMA PET?
- Published in:
- Therapeutic Advances in Medical Oncology, 2019, v. 11, p. 1, doi. 10.1177/1758835919876828
- By:
- Publication type:
- Article
The Role of Cancer-Testis Antigens as Predictive and Prognostic Markers in Non-Small Cell Lung Cancer.
- Published in:
- PLoS ONE, 2013, v. 8, n. 7, p. 1, doi. 10.1371/journal.pone.0067876
- By:
- Publication type:
- Article
Predictors of real‐world utilisation of docetaxel combined with androgen deprivation therapy in metastatic hormone‐sensitive prostate cancer.
- Published in:
- Internal Medicine Journal, 2022, v. 52, n. 8, p. 1339, doi. 10.1111/imj.15288
- By:
- Publication type:
- Article
Radiation Recall Dermatitis Induced by Pazopanib.
- Published in:
- Oncology Research & Treatment, 2013, v. 36, n. 11, p. 674, doi. 10.1159/000355649
- By:
- Publication type:
- Article
Relationship between Circulating Lipids and Cytokines in Metastatic Castration-Resistant Prostate Cancer.
- Published in:
- Cancers, 2021, v. 13, n. 19, p. 4964, doi. 10.3390/cancers13194964
- By:
- Publication type:
- Article
A randomized phase II efficacy and safety study of vandetanib (ZD6474) in combination with bicalutamide versus bicalutamide alone in patients with chemotherapy naïve castration-resistant prostate cancer.
- Published in:
- 2014
- By:
- Publication type:
- Journal Article
A randomized phase II efficacy and safety study of vandetanib (ZD6474) in combination with bicalutamide versus bicalutamide alone in patients with chemotherapy naïve castration-resistant prostate cancer.
- Published in:
- Investigational New Drugs, 2014, v. 32, n. 4, p. 746, doi. 10.1007/s10637-014-0091-8
- By:
- Publication type:
- Article
Neurolymphomatosis: diagnosis, management, and outcomes in patients treated with rituximab.
- Published in:
- Neuro-Oncology, 2010, v. 12, n. 2, p. 212, doi. 10.1093/neuonc/nop021
- By:
- Publication type:
- Article
Safety, pharmacokinetic, pharmacodynamic and clinical activity of molibresib for the treatment of nuclear protein of the testis carcinoma and other cancers: Results of a Phase I/II open‐label, dose escalation study.
- Published in:
- International Journal of Cancer, 2022, v. 150, n. 6, p. 993, doi. 10.1002/ijc.33861
- By:
- Publication type:
- Article
Real‐world first‐line systemic therapy patterns in metastatic castration‐resistant prostate cancer.
- Published in:
- BJUI Compass, 2022, v. 3, n. 3, p. 205, doi. 10.1002/bco2.129
- By:
- Publication type:
- Article
Use of Ultrasonography Facilitates Noninvasive Evaluation of Lymphadenopathy in a Lymph Node Diagnostic Clinic.
- Published in:
- 2021
- By:
- Publication type:
- journal article
Functional analysis of androgen receptor mutations that confer anti-androgen resistance identified in circulating cell-free DNA from prostate cancer patients.
- Published in:
- Genome Biology, 2016, v. 17, p. 1, doi. 10.1186/s13059-015-0864-1
- By:
- Publication type:
- Article
Clinical Trial Protocol for VIOLET: A Single-Center, Phase I/II Trial Evaluation of Radioligand Treatment in Patients with Metastatic Castration-Resistant Prostate Cancer with [<sup>161</sup>Tb]Tb-PSMA-I&T.
- Published in:
- Journal of Nuclear Medicine, 2024, v. 65, n. 8, p. 1, doi. 10.2967/jnumed.124.267650
- By:
- Publication type:
- Article
<sup>177</sup>Lutetium-PSMA-617 and idronoxil (NOX66) in men with end-stage metastatic castration-resistant prostate cancer (LuPIN): Patient outcomes and predictors of treatment response of a Phase I/II trial.
- Published in:
- Journal of Nuclear Medicine, 2021, v. 62, n. 12, p. 1, doi. 10.2967/jnumed.121.262552
- By:
- Publication type:
- Article
<sup>177</sup>Lutetium-PSMA-617 and idronoxil (NOX66) in men with end-stage metastatic castration-resistant prostate cancer (LuPIN): Patient outcomes and predictors of treatment response of a Phase I/II trial.
- Published in:
- Journal of Nuclear Medicine, 2021, v. 62, n. 11, p. 1, doi. 10.2967/jnumed.121.262552
- By:
- Publication type:
- Article
<sup>177</sup>Lutetium-PSMA-617 and idronoxil (NOX66) in men with end-stage metastatic castration-resistant prostate cancer (LuPIN): Patient outcomes and predictors of treatment response of a Phase I/II trial.
- Published in:
- Journal of Nuclear Medicine, 2021, v. 62, n. 10, p. 1, doi. 10.2967/jnumed.121.262552
- By:
- Publication type:
- Article
<sup>177</sup>Lutetium-PSMA-617 and idronoxil (NOX66) in men with end-stage metastatic castration-resistant prostate cancer (LuPIN): Patient outcomes and predictors of treatment response of a Phase I/II trial.
- Published in:
- Journal of Nuclear Medicine, 2021, v. 62, n. 8, p. 1, doi. 10.2967/jnumed.121.262552
- By:
- Publication type:
- Article
A retrospective, Canadian multi-center study examining the impact of prior response to abiraterone acetate on efficacy of docetaxel in metastatic castration-resistant prostate cancer.
- Published in:
- Prostate, 2014, v. 74, n. 15, p. 1544, doi. 10.1002/pros.22872
- By:
- Publication type:
- Article
Is genetic testing coming of age in advanced prostate cancer?
- Published in:
- BJU International, 2023, v. 132, n. 5, p. 496, doi. 10.1111/bju.16139
- By:
- Publication type:
- Article
Prostate‐specific membrane antigen positron emission tomography‐computed tomography use prior to systemic therapy in metastatic castration‐resistant prostate cancer.
- Published in:
- BJU International, 2023, v. 131, n. 2, p. 179, doi. 10.1111/bju.15930
- By:
- Publication type:
- Article
ENZA‐p trial protocol: a randomized phase II trial using prostate‐specific membrane antigen as a therapeutic target and prognostic indicator in men with metastatic castration‐resistant prostate cancer treated with enzalutamide (ANZUP 1901)
- Published in:
- BJU International, 2021, v. 128, n. 5, p. 642, doi. 10.1111/bju.15491
- By:
- Publication type:
- Article
Real‐world use of first‐generation antiandrogens: impact on patient outcomes and subsequent therapies in metastatic castration‐resistant prostate cancer.
- Published in:
- BJU International, 2021, v. 128, p. 18, doi. 10.1111/bju.15364
- By:
- Publication type:
- Article
UpFrontPSMA: a randomized phase 2 study of sequential <sup>177</sup>Lu‐PSMA‐617 and docetaxel vs docetaxel in metastatic hormone‐naïve prostate cancer (clinical trial protocol).
- Published in:
- BJU International, 2021, v. 128, n. 3, p. 331, doi. 10.1111/bju.15384
- By:
- Publication type:
- Article
Prostate‐specific membrane antigen theranostics in advanced prostate cancer: an evolving option.
- Published in:
- BJU International, 2020, v. 126, n. 5, p. 525, doi. 10.1111/bju.15143
- By:
- Publication type:
- Article
Novel agents for metastatic hormone‐sensitive prostate cancer – a practice guide for urologists.
- Published in:
- BJU International, 2020, v. 125, n. 3, p. 342, doi. 10.1111/bju.14936
- By:
- Publication type:
- Article
TheraP: a randomized phase 2 trial of <sup>177</sup>Lu‐PSMA‐617 theranostic treatment vs cabazitaxel in progressive metastatic castration‐resistant prostate cancer (Clinical Trial Protocol ANZUP 1603).
- Published in:
- BJU International, 2019, v. 124, p. 5, doi. 10.1111/bju.14876
- By:
- Publication type:
- Article
Going nuclear: it is time to embed the nuclear medicine physician in the prostate cancer multidisciplinary team.
- Published in:
- BJU International, 2019, v. 124, n. 4, p. 551, doi. 10.1111/bju.14814
- By:
- Publication type:
- Article
Patterns of care for metastatic renal cell carcinoma in Australia.
- Published in:
- BJU International, 2015, v. 116, p. 36, doi. 10.1111/bju.13176
- By:
- Publication type:
- Article
Uro-oncology multidisciplinary meetings at an Australian tertiary referral centre - impact on clinical decision-making and implications for patient inclusion.
- Published in:
- BJU International, 2014, v. 114, p. 50, doi. 10.1111/bju.12764
- By:
- Publication type:
- Article
USANZ: Time-trends in use and impact on outcomes of perioperative chemotherapy in patients treated with radical cystectomy for urothelial bladder cancer.
- Published in:
- BJU International, 2013, v. 112, p. 74, doi. 10.1111/bju.12384
- By:
- Publication type:
- Article
Changes in plasma biomarkers following treatment with cabozantinib in metastatic castration-resistant prostate cancer: a post hoc analysis of an extension cohort of a phase II trial.
- Published in:
- 2016
- By:
- Publication type:
- journal article
Modern paradigms for prostate cancer detection and management.
- Published in:
- Medical Journal of Australia, 2022, v. 217, n. 8, p. 424, doi. 10.5694/mja2.51722
- By:
- Publication type:
- Article
Understanding the diagnosis of prostate cancer.
- Published in:
- Medical Journal of Australia, 2020, v. 213, n. 9, p. 424, doi. 10.5694/mja2.50820
- By:
- Publication type:
- Article
Radiotherapy and immunotherapy: a synergistic effect in cancer care.
- Published in:
- 2019
- By:
- Publication type:
- journal article